Sermorelin

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29), the fragment associated with GHRH activity in the published literature. As a member of the growth hormone secretagogue class, it is supplied in lyophilized injectable form for licensed research and professional use. This compound is not approved by the FDA for therapeutic use and is provided strictly as a reference material for qualified practitioners and investigators. It is frequently examined in the scientific literature within the broader context of the somatotropic (growth hormone) axis and endocrine signaling. The information below is intended as professional catalog reference only and is not patient-directed marketing; individual results vary and no outcomes are claimed or implied.

• Investigated in research literature as a tool compound for studying endogenous growth hormone secretion and the GHRH receptor pathway
• Examined in preclinical and exploratory studies relating to age-associated changes in the somatotropic axis
• Studied as a comparator to recombinant growth hormone in models of pulsatile hormone release
• Explored in research contexts addressing sleep architecture, recovery, and body-composition signaling within the GH/IGF-1 axis
• Used in laboratory settings to probe pituitary responsiveness and feedback regulation

Supplied as a lyophilized powder. For reference, sermorelin is commonly reconstituted with bacteriostatic water for injection added slowly against the vial wall and gently swirled rather than shaken to preserve peptide integrity; avoid vigorous agitation. Lyophilized vials are typically stored refrigerated (approximately 2-8 C) and kept away from heat, and the unopened powder may tolerate freezing for longer-term storage per institutional practice. After reconstitution, the solution is generally kept refrigerated, protected from light, and used within the window indicated by the laboratory's stability data; discard if discoloration or particulate matter is observed. Protect from light and excessive temperature fluctuations throughout handling. This is reconstitution, storage, and handling reference information only and is not medical advice; all clinical protocols, including any dosing and administration decisions, are determined solely at the discretion of the licensed ordering provider.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

Sermorelin is described in the literature as a growth hormone-releasing hormone analog that binds to GHRH receptors on somatotroph cells of the anterior pituitary. This receptor interaction is reported to stimulate the synthesis and pulsatile release of endogenous growth hormone in a manner reported to preserve physiological feedback mechanisms, including modulation by somatostatin and downstream IGF-1 signaling. Because the proposed action is described as working upstream through native regulatory pathways rather than supplying exogenous growth hormone directly, it is often studied as a tool for examining intact axis dynamics. These mechanistic descriptions reflect findings reported in research settings; effects observed in such contexts may not generalize, and individual results vary.